Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to understand whether there is any difference in the
amount of tasimelteon (including its breakdown products) in the blood in individuals with
mild or moderate liver disease compared to individuals who have normal liver function.